Literature DB >> 4026990

Nonenzymatic glycation of immunoglobulins leads to an impairment of immunoreactivity.

R Dolhofer, E A Siess, O H Wieland.   

Abstract

Incubation of purified human and rabbit immunoglobulin G with glucose leads to covalent incorporation of the sugar into the protein, depending on glucose concentration, incubation time and pH. Furthermore, the level of glycated immunoglobulin G from normal and diabetic subjects has been determined using the thiobarbituric acid reaction. The median for glycated immunoglobulin G, expressed as mmol 5-hydroxymethylfurfural per mol IgG, obtained from 20 normal and 29 diabetic subjects was 62 and 107, respectively. Glucose incubation of immunoglobulin G purified from rabbit anti-human-transferrin serum, from human anti-varicella/zoster virus serum and from human anti-lues-spirochete serum, respectively, leads to a marked decrease in biological activity, as determined in a micro complement fixation test. Inactivation of specific antibody was dependent on incubation time and glucose concentration employed. Loss in complement-fixing activity was observed at glycation levels well comparable to those found in diabetics.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026990     DOI: 10.1515/bchm3.1985.366.1.361

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  14 in total

1.  Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

Authors:  T Mitsuhashi; Y M Li; S Fishbane; H Vlassara
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 2.  Glycation of antibodies: Modification, methods and potential effects on biological functions.

Authors:  Bingchuan Wei; Kelsey Berning; Cynthia Quan; Yonghua Taylor Zhang
Journal:  MAbs       Date:  2017-03-08       Impact factor: 5.857

3.  Inhibiting Effect of Zinc Oxide Nanoparticles on Advanced Glycation Products and Oxidative Modifications: a Potential Tool to Counteract Oxidative Stress in Neurodegenerative Diseases.

Authors:  Jalaluddin M Ashraf; Mohammad Azam Ansari; Sana Fatma; Saleh M S Abdullah; Johar Iqbal; Aymen Madkhali; Al Hassan Hamali; Saheem Ahmad; Ahmed Jerah; Valentina Echeverria; George E Barreto; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2018-02-08       Impact factor: 5.590

4.  Influence of hyperglycemia on Ca2+-Mg2+ -ATPase of red blood cells from diabetic patients.

Authors:  W Schaefer; J Beeker; F A Gries
Journal:  Klin Wochenschr       Date:  1988-05-16

5.  Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-04-30       Impact factor: 4.009

6.  Glycation increases the vascular clearance rate of IgG in mice.

Authors:  D M Kennedy; A W Skillen; C H Self
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

7.  Non enzymatic glycosylation of IgG and their urinary excretion in patients with diabetic nephropathy.

Authors:  Kinnari Mistry; Kiran Kalia
Journal:  Indian J Clin Biochem       Date:  2009-07-09

8.  Glycation of monoclonal antibodies impairs their ability to bind antigen.

Authors:  D M Kennedy; A W Skillen; C H Self
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

9.  Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.

Authors:  Xiaotian Zhong; Jill F Wright
Journal:  Int J Cell Biol       Date:  2013-04-18

10.  Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG.

Authors:  A Lapolla; D Fedele; M Garbeglio; L Martano; R Tonani; R Seraglia; D Favretto; M A Fedrigo; P Traldi
Journal:  J Am Soc Mass Spectrom       Date:  2000-02       Impact factor: 3.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.